SequelSEC

Arbutus Biopharma Corp ABUS

Pharmaceutical Preparations · CIK 0001447028 · Fiscal year ends 1231

Revenue
$181.72M
Fiscal year ended 2026-06-30
Operating income
$149.00M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$472.13MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$2.42Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue33.5×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity6.2×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
CapEx / revenue0.0%0th
Current ratio15.73x92th
Revenue YoY growth128.2%85th
SBC / revenue49.4%62th
FCF margin-281.5%39th
Net margin-237.9%46th
Operating margin-271.0%48th
R&D / revenue179.2%49th

Arbutus Biopharma Corp (ABUS) reported revenue of $181.72M and net income of $153.05M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Arbutus Biopharma Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Arbutus Biopharma Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$181.72M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income$149.00M
Net income$153.05M
Research & development$17.80M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$16.49M
Selling & marketingUnavailable

Balance

Arbutus Biopharma Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$19.17M
Total assets$274.02M
Current assets$273.88M
Total liabilities$15.29M
Current liabilities$3.36M
Total equity incl. NCI$258.73M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$369.00K
GoodwillUnavailable
Long-term debt$0
Accounts payableUnavailable

Cash flow

Arbutus Biopharma Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$24.62M
Capital expendituresUnavailable
Investing cash flow-$10.84M
Financing cash flow$17.25M
Net change in cash-$18.24M
Stock-based compensation$5.51M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Arbutus Biopharma Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross marginUnavailable
Operating margin82.0%
FCF marginUnavailable
SBC / revenue3.0%
Current ratio81.42x
Revenue YoY growth1078.8%
Net margin84.2%
R&D / revenue9.8%
CapEx / revenueUnavailable
Long-term debt / equity0.00x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ABUS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-23View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-06View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.